drugset
drugset / Trial / NCT04298983

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

NCT04298983 ↗

Phase 2 Terminated 9 enrolled University of Alabama at Birmingham Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation therapy (RT) and androgen deprivation therapy (ADT).

Timeline

Start
2021-02-25
Primary completion
2024-07-18
Completion
2024-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 150 mg Oral

Indications

prostate cancer